Lonapegsomatropin: Difference between revisions
Content deleted Content added
template bare URL; + cite |
m Open access bot: doi added to citation with #oabot. |
||
| Line 114: | Line 114: | ||
== Further reading == |
== Further reading == |
||
{{refbegin}} |
{{refbegin}} |
||
* {{cite journal | vauthors = Thornton PS, Maniatis AK, Aghajanova E, Chertok E, Vlachopapadopoulou E, Lin Z, Song W, Christoffersen ED, Breinholt VM, Kovalenko T, Giorgadze E, Korpal-Szczyrska M, Hofman PL, Karpf DB, Shu AD, Beckert M | display-authors = 6 | title = Weekly Lonapegsomatropin in Treatment-Naïve Children with Growth Hormone Deficiency: The Phase 3 heiGHt Trial | journal = The Journal of Clinical Endocrinology and Metabolism | volume = | issue = | pages = | date = July 2021 | pmid = 34272849 | doi = 10.1210/clinem/dgab529 }} |
* {{cite journal | vauthors = Thornton PS, Maniatis AK, Aghajanova E, Chertok E, Vlachopapadopoulou E, Lin Z, Song W, Christoffersen ED, Breinholt VM, Kovalenko T, Giorgadze E, Korpal-Szczyrska M, Hofman PL, Karpf DB, Shu AD, Beckert M | display-authors = 6 | title = Weekly Lonapegsomatropin in Treatment-Naïve Children with Growth Hormone Deficiency: The Phase 3 heiGHt Trial | journal = The Journal of Clinical Endocrinology and Metabolism | volume = | issue = | pages = | date = July 2021 | pmid = 34272849 | doi = 10.1210/clinem/dgab529 | doi-access = free }} |
||
{{refend}} |
{{refend}} |
||
Revision as of 05:14, 20 September 2021
| Clinical data | |
|---|---|
| Trade names | Skytrofa |
| Other names | Lonapegsomatropin-tcgd; rhGH-PEG; ACP-011; ΤransConPEG hGh; WHO-10598 |
| License data | |
| Routes of administration | Subcutaneous injection |
| Drug class | Growth hormone receptor agonist |
| ATC code |
|
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
| PubChem SID | |
| DrugBank | |
| UNII | |
| KEGG | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C1051H1627N269O317S9[C2H4O]4n |
Lonapegsomatropin, sold under the brand name Skytrofa, is a human growth hormone used for the treatment of growth hormone deficiency.[1] Lonapegsomatropin is a prodrug of somatropin.[1]
Lonapegsomatropin was approved for medical use in the United States in August 2021.[1][2][3]
Medical uses
Lonapegsomatropin is a growth hormone therapy indicated to treat growth hormone deficiency.[1]
References
- ^ a b c d e "Highlights of Prescribing Information: SKYTROFATM (lonapegsomatropin-tcgd) for injection, for subcutaneous use" (PDF). U.S. Food and Drug Administration.
- ^ a b "Skytrofa: FDA-Approved Drugs". U.S. Food and Drug Administration (FDA). Retrieved 25 August 2021.
- ^ "Ascendis Pharma A/S Announces U.S. Food and Drug Administration Approval of Skytrofa (lonapegsomatropin-tcgd), the First Once-weekly Treatment for Pediatric Growth Hormone Deficiency". Ascendis Pharma (Press release). 25 August 2021. Retrieved 25 August 2021.
Further reading
- Thornton PS, Maniatis AK, Aghajanova E, Chertok E, Vlachopapadopoulou E, Lin Z, et al. (July 2021). "Weekly Lonapegsomatropin in Treatment-Naïve Children with Growth Hormone Deficiency: The Phase 3 heiGHt Trial". The Journal of Clinical Endocrinology and Metabolism. doi:10.1210/clinem/dgab529. PMID 34272849.
External links
- "Lonapegsomatropin". Drug Information Portal. U.S. National Library of Medicine.
- Clinical trial number NCT02781727 for "A Phase 3 Trial of the Safety, Tolerability and Efficacy of TransCon hGH Weekly Versus Daily hGH in Children With Growth Hormone Deficiency (GHD)" at ClinicalTrials.gov
 | This hormonal preparation article is a stub. You can help Wikipedia by expanding it. |